IDIX is formally joining the set of companies running all oral HCV studies!
According to today’s CC, as soon as IDIX has adequate safety data from the phase-1b monotherapy trial of IDX320 (which begins enrolling patients any day), IDIX will start a drug-drug-interaction study of IDX184 + IDX320 in healthy volunteers during the current quarter. No adverse interaction between these drugs is anticipated, but the DDI study must be run as a prelude to running a trial of IDX184 + IDX320 in HCV patients.
Pending FDA agreement on trial design and a satisfactory outcome to the aforementioned DDI study, IDIX will start a 14- or 28-day phase-2a trial of IDX184 + IDX320 in HCV patients during 2H10.
Since IDIX revealed in January that IDX320 was superseding IDX136/IDX316 (#msg-45598790), it’s become increasingly clear that IDIX has big plans for this compound. IDIX’s PR’s at EASL featured IDX320 prominently (#msg-49055353), but today’s revelation of the plan to run a phase-2a study of IDX184 + IDX320 during 2010 is the biggest news yet for IDX320, by far.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.